Last reviewed · How we verify
Iobenguane I -123 Injection
Iobenguane I-123 is a radiolabeled norepinephrine analog that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing for diagnostic imaging via single-photon emission computed tomography (SPECT).
Iobenguane I-123 is a radiolabeled norepinephrine analog that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing for diagnostic imaging via single-photon emission computed tomography (SPECT). Used for Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma, Imaging of neuroblastoma in pediatric patients.
At a glance
| Generic name | Iobenguane I -123 Injection |
|---|---|
| Also known as | AdreView, Iobenguane I-123 Injection |
| Sponsor | GE Healthcare |
| Drug class | Radiopharmaceutical diagnostic agent |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Iobenguane I-123 mimics norepinephrine and is taken up by the norepinephrine transporter (NET) on neuroendocrine cells, concentrating in tumors with high sympathetic innervation or neuroendocrine differentiation. The iodine-123 radioisotope emits gamma radiation that is detected by SPECT cameras, enabling visualization and localization of neuroendocrine tumors. This mechanism makes it useful for both diagnostic imaging and risk stratification in neuroendocrine malignancies.
Approved indications
- Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma
- Imaging of neuroblastoma in pediatric patients
Common side effects
- Radiation exposure
- Allergic reaction to iodine
- Hypertensive crisis (in pheochromocytoma patients)
Key clinical trials
- Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors (EARLY_PHASE1)
- Imaging With a Radio Tracer to Guide VT Ablations (NA)
- A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma (PHASE1, PHASE2)
- Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma (PHASE3)
- International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device (PHASE3)
- 123I-mIBG SPECT Imaging (PHASE3)
- Autonomic Innervation and MIBG Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |